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CHAPTER 1: GENERAL INTRODUCTION 
 
Introduction 
Mycobacterium bovis is the causative agent of tuberculosis in cattle. M. bovis is a 
member of the Mycobacterium tuberculosis complex (Mtbc) which also includes M. 
tuberculosis, M. caprae, M. microti, M. africanum, M. canetti, M. pinnipedii, and M. 
bovis Bacillus Calmette Guerin (BCG) (28). Unlike most of the organisms in this group, 
M. bovis has a broad host range including; cattle, cervids, badgers, humans, and many 
other animals (52).  
Currently, M. bovis is the most common organism isolated from cattle with 
tuberculosis (TB). M. tuberculosis can also infect cattle; however, it is not as virulent as 
M. bovis in cattle (36, 75). The infective dose of M. bovis is low with studies 
demonstrating less than 10 viable bacilli are sufficient to cause infection (32); however, 
multiple factors influence transmission such as frequency of excretion, period of 
communicability, and route, just to name a few. (49).  
The broad host range, low infective dose, and presence of wildlife reservoirs make 
eradication of bovine TB difficult. However, several countries, including the United 
States, have TB eradication and control programs in place to monitor and manage these 
reservoirs as well as the cattle (31). Current bovine TB eradication and control programs 
generally rely on slaughter surveillance as well as test and cull strategies (75). However, 
improved ante mortem diagnostic tests are needed. 
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Thesis Organization 
 
This thesis includes one manuscript. The manuscript is preceded by a general 
introduction chapter and followed by a general conclusions chapter. The manuscript in 
this thesis is an evaluation of Mycobacterium antigen-specific peptide cocktails and 
purified protein derivatives for their use in the Interferon-gamma (IFN-γ) release assay 
(Bovigam) using experimentally challenged animals and naturally infected animals with 
M. bovis. The general introduction chapter includes a literature review of the biology of 
M. bovis, the cell-mediated immune response to M. bovis, current ante-mortem assays 
including skin tests and the IFN-γ release assay, improvements of ante-mortem tests 
through identification and use of Mtbc-specific proteins, and incorporation of Mtbc-
specific antigens and evaluation of PPDs in the IFN-γ release assay. The general 
conclusions chapter includes a general discussion regarding the components of this thesis 
and suggestions for future research. References to cited papers within each chapter are 
included at the end of each chapter. 
 
Literature Review 
 
Biology of Mycobacterium bovis 
Organisms from the genus Mycobacterium are slow growing, acid-fast bacteria 
that are rod shaped or slightly curved (77). They were first identified as pathogenic 
bacteria with Koch’s discovery of M. tuberculosis bacilli in 1882 as the cause of TB in 
humans (90). Most bacteria in the genus Mycobacterium are saprophytic organisms 
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commonly found in the environment with relatively few causing diseases in animals or 
immunosuppresed individuals (52, 77).  
Pathogenic species of Mycobacterium can be classified based on their ability to 
cause tuberculous infections. These can be categorized as Mtbc or non-tuberculous 
Mycobacteria spp (NTMs). An example of an NTM is M. avium subsp. paratuberculosis, 
the causative agent of Johne’s disease in cattle which is characterized by a chronic 
wasting in cattle. Other, potentially pathogenic NTMs include M. kansasii, M. marinum 
and M. avium complex species (52). These are known to cause disease in some cases, 
such as immunosuppressed individuals; however, they are generally opportunistic and 
less pathogenic than those in the Mtbc. Human-to-human transmission of NTM species is 
not known to occur and they can be found growing in the environment (76). NTMs are 
important in diagnostic tests for TB due to the conservation of antigens within the 
Mycobacterium genus which can interfere with test results due to cross reactivity. 
Mycobacterium spp in the Mtbc cause infections that are debilitating or even life 
threatening and have been classified as obligate pathogens (52).  Mtbc species are 
generally not found free growing in the environment and usually require a host to 
multiply. They can be transmitted directly via aerosol, feces, sputum, body tissues, urine, 
semen, and milk and indirectly via exposure to contaminated feed bunks, water troughs, 
equipment, and other items that are shared by cattle within a herd (49)/ 
Mycobacterium bovis was first discovered in 1898 by isolation of tubercle bacilli 
from bovine sputum, which was inoculated into rabbits. Upon examination, it was 
observed to be more virulent than human tubercle bacilli in rabbits based on pathological 
findings (99).  
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Today, less than 2% of TB cases in humans are caused by M. bovis; however, it is 
more common in certain geographic regions (106). An example of this is at the U.S-
Mexico border where over the last decade 7% of all TB cases resulted from infection 
with M. bovis (61). Most patients presented with extra-pulmonary disease and infection 
was likely due to consumption of unpasteurized, TB contaminated milk (61). Common 
disease sequalae resulting from M. bovis infections in humans include: lymphadenitis 
(particularly in children), extra-pulmonary disease, and pulmonary disease (e.g. from 
inhalation of droplets from M. bovis- infected cattle or dissemination from other sites) 
(29) M. bovis can also be transmitted from cattle to humans. This makes M. bovis both an 
occupational hazard as well as a zoonotic hazard (42, 49). 
Experimental studies with M. bovis in animals have demonstrated that the 
immune response and disease severity can vary based on the route of infection as well as 
the dose administered  (71, 112, 116). Such routes that have been examined are 
intratracheal, oral, intravenous, intraperitoneal, and aerosol (116). With most hosts, the 
most common route of transmission is via aerosol (69). Oral ingestion is also possible 
through feed or water contaminated with mucous, feces, or urine from an infected animal. 
It can also be transmitted to offspring via TB contaminated milk while nursing (44). It is 
also important to note that the location of the lesion within the host can also affect how it 
is shed (43). Transcutaneous infection has also been seen as a result of infected animal 
bites. This has been documented in domestic cats, ferrets, and European badgers (84, 47). 
These animals are considered to be reservoirs of M. bovis. 
 White-tailed deer (i.e. in northern Michigan) are a known reservoir for M. bovis 
in the United States (74). Animals such as the European badger in the United Kingdom as 
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well as brushtail possums in New Zealand are also reservoirs of bovine TB due to their 
close contact with not only one another, but with confined animals while foraging for 
food (23, 19). Disease that is seen in reservoir animals is similar to that seen in cattle with 
M. bovis and humans with TB infection. With that said, subtle differences in the immune 
response and pathological progression of disease to M. bovis infection of possums, 
badgers, deer, and other hosts of M. bovis are seen.  
With the development of genome sequencing, differences between species can be 
examined. M. bovis and M. tuberculosis were found to be 99.95% identical; however, M. 
bovis has lost several genes when compared to M. tuberculosis (46). For example, one 
point mutation in M. bovis causes it to be resistant to pyrazinamide, while M. tuberculosis 
is not susceptible. Other deletions may affect host adaptation (12). A number of 
differentiating features between M. bovis and M. tuberculosis have been observed 
through bacterial culture as well. A study by Konno and colleagues discovered M. 
tuberculosis produces nicotinic acid whereas M. bovis does not (59). A later study by 
Virtanen showed M. bovis does not produce nitrate reductase, which is an enzyme 
produced by M. tuberculosis and other mycobacterium species (109). It has also been 
demonstrated that glycerol can inhibit M. bovis growth, but not M. tuberculosis. 
Numerous distinguishing biochemical and metabolic features have been previously 
reviewed (46, 86). Although there are differentiating features, the genome similarity of 
M. bovis and M. tuberculosis has some advantages. Foremost was the development of 
tuberculin as a diagnostic tool and BCG as a possible vaccine for both M. bovis infection 
in cattle and M. tuberculosis infection of humans. These discoveries highlight the “One 
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Health” aspect of TB research and benefits of co-discovery for veterinary and medical 
applications (119). 
Tuberculin was developed in the 1890s by Robert Koch and is a mixture of 
proteins that have been isolated from a Mycobacterial culture (67). Investigating 
veterinarians in Russia, Denmark, the United Kingdom, and the United States noticed 
that when an animal was injected with a preparation of glycerin extract of tubercle bacilli, 
Koch’s ‘Old Tuberculin’, and temperature was monitored for 24 hours, infected animals 
would show an increase in temperature compared to non-infected animals (64, 94, 118). 
This is the same tuberculin that was first used for TB skin testing in humans. The 
currently used tuberculins are referred to as purified protein derivatives (PPD) (67). 
These crude protein extracts have been through a purification process in which proteins, 
and other components such as lipids, that resulted in non-specific reactions have been 
removed (127). The purification process has resulted in a current PPD with a higher 
sensitivity and specificity (94, 127). However, PPDs are unable to distinguish BCG 
vaccination status from infection. 
BCG is the designation given to an attenuated strain of M. bovis, the first one 
having been discovered by Calmette and Guérin in the early 1900s through in vitro 
passage of a virulent bovine isolate on potato slices (16, 40).  They further examined it as 
a possible vaccine due to its retention of core antigens. They demonstrated that animals 
that received BCG and were later challenged with M. bovis, showed no signs of infection 
(64). Today several BCG vaccines have been created using various strains, processes, and 
number of passages of virulent M. bovis that results in differences at the genome level 
between BCG strains (10). BCG’s protective immunity is thought to depend on the 
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production of IFN-γ upon CD4+ T cell activation that in turn activates macrophages to 
kill M. bovis (2, 53).  However, the effectiveness of BCG in preventing TB in humans 
and animals is controversial; it can prevent TB in children, but does not prevent 
reactivation of a preexisting infection in older people (22). BCG vaccination field trials 
have shown mixed results, ranging from 0 to 80% efficacy (22). Despite these findings, a 
majority of studies report that most people vaccinated with BCG will switch from skin 
test negative to positive (37). The United States does not BCG vaccinate due to its ability 
to render the skin test ineffective as a means of primary diagnosis. However, it has been 
shown that this positive skin test due to vaccination wanes over time (37, 101). Variations 
in efficacy of the vaccine as well as conversion to skin test positive have also been seen 
in cattle studies involving BCG vaccination (14). Overall, the failure of the BCG vaccine 
to give high protection rates indicate an improved vaccine is needed (39), as well as 
improved diagnostic assays to differentiate M. bovis infection from vaccination. Current 
diagnostic assays to detect bovine TB rely on the measurement of cell-mediated immune 
(CMI) responses to M. bovis. 
 
CMI response to M. bovis. 
M. bovis is spread from animal to animal via both direct contact (e.g. aerosol 
droplets from infected animals) and indirect contact (e.g. contaminated feed, feed-bunks, 
equipment, etc). M. bovis infection begins most commonly with the inhalation of the 
mycobacteria where they gain passage into the pulmonary alveoli (71, 78). Alveolar 
macrophages recognize M. bovis by their pattern recognition and toll-like receptors 
(TLR). Currently, it is known that TLR2 can recognize 99 lipoproteins, 
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Phosphatidylmyo-inositol mannosides, and lipoarabinomannan that are present on the 
surface of M. bovis (9). Following binding there is internalization of the bacteria into a 
vesicle. In M. tuberculosis challenged mice it was found that once inside the macrophage 
TLR9 senses mycobacterial DNA and signals cytokine production in macrophages and 
dendritic cells (7).  
Once the mycobacteria are internalized, they inhibit the macrophages from 
completing the phagolysosome fusion that prevents the vesicle from acidifying (102, 
105). Infected macrophages experience a reduction in oxidative burst and a reduction in 
IL-12 production. IL-12 is necessary for stimulation of the T helper 1 (Th1) responses 
critical for IFN-γ production (24). The bacteria multiply within the phagosome and when 
the infected macrophage undergoes apoptosis, the mycobacteria are able to infect other 
nearby macrophages (27, 30, 105). As more macrophages become infected, the cytokine 
and chemokine levels increase resulting in an influx of neutrophils, inactivated 
macrophages, fibroblasts, and dendritic cells to the area (27, 103). This is followed by 
initiation of the cell mediated immune (CMI) response. This is seen by the presence of 
CD4+ and CD8+ T cells as well as B cells at the site of infection (41). 
 CD8+ T cells are important to contain the infection. They kill infected cells that 
have failed to destroy the bacteria (41). The importance of the CD8+ T cell response has 
been demonstrated by Sousa and colleagues who determined that mice lacking B2-
microglobulin or CD8+ T cells are more susceptible to TB than are normal mice (100). 
The CD4 T cells can be broken down into two different classes based on their 
lymphokine profiles (91). The Th1 cells produce interleukin-2 and IFN-γ. Th1 cells 
stimulate macrophage activation and are necessary for controlling M. bovis infections 
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(87). IFN-γ mediates mycobacterial killing through enhancement of phagosome 
maturation (65,128). The type 2 helper cells (Th2) produce interleukin 4, 13, and 10, 
which is not as helpful as IFN-γ in clearing infection (72). However, the role of Th2 and 
antibody is still unclear. 
Thorn and Morris demonstrated that the immune response to M. bovis was 
primarily cell-mediated rather than humoral (107). Therefore, the development of assays 
measuring components of the CMI response became extensively studied.  Responses by 
CD4 cells in controlling M. bovis infection have been incorporated for use in current 
diagnostic assays. Such responses include production of IFN-γ (122) as well as the 
development of memory T cells to M. bovis (26). IFN-γ stimulates activation of 
macrophages, which leads to the activation of the oxidative burst within the macrophage 
(3, 87). It also mediates mycobacterial killing enhancing phagosome maturation (65). 
Knocking out IFN-γ production in mice resulted in increased susceptibility to TB 
infections (25). Studies in mice and humans have shown that IFN-γ levels correlate with 
disease progression (2, 34). It is also produced in high quantities in vitro, which can then 
be measured by an enzyme immunoassay (EIA) and is not readily consumed during short 
term culturing (122, 125). The importance in IFN-γ production to control infection makes 
it a reliable indicator of bovine TB. In addition to IFN-γ production, the memory 
response can be established by infection by mycobacterium, non-pathogenic 
environmental mycobacteria, or BCG vaccination (4). The development of memory T 
cells sensitized to proteins and antigens of M. bovis the basis of the ante-mortem 
tuberculin-skin test.  
 
10 
 
Current ante-mortem diagnostic tests 
M. bovis infection elicits a robust CMI response in its host, which is 
predominantly T lymphocyte dependent (31). This makes ante-mortem tests detecting 
markers of CMI responses important in controlling the spread of bovine TB since they 
can identify infected animals early (66).  Current ante-mortem diagnosis is dependent on 
the delayed type hypersensitivity (DTH) response elicited by skin testing, similar to that 
used in humans, and IFN-γ release assays.  
 
Skin Test 
In the United States, there are two types of procedures for skin testing in animals; the 
caudal fold test (CFT) and the comparative cervical skin test (CCT) (70, 129).  The 
caudal fold skin test (CFT) is used as a primary test in herds where TB status of the 
animals is unknown (129) and retesting of is generally by CCT (70). A veterinarian 
performs the CFT by injecting PPD, which is comprised of water-soluble fractions of 
heat –treated products from M. bovis (PPDb), into the caudal tail fold (i.e., two folds of 
skin located under the base of the tail (5, 31, 129).  
 Antigen presenting cells ingest the proteins, break them down, and present parts of 
them on their surface (54). Circulating CD4 memory T cells will bind and activate if 
there has been prior exposure, or sensitization, to the antigens (107). Sensitization can 
occur by active or clinically resolved TB infection, cross-reactivity to mycobacterium 
conserved antigens, or BCG vaccination (4). Upon activation the T cells release 
cytokines, such as TNF-alpha (TNF-α), which signals for recruitment of monocytes, 
macrophages, and additional T cells to the area (54).   
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TNF-α activates the vascular endothelium in local blood vessels resulting in 
inflammatory effects. These inflammatory effects include the loosening of the tight 
junction between endothelial cells. This allows fluid to leak out of blood vessels causing 
swelling at the injection site (54). The activated endothelium also begins to express 
adhesion molecules, which allows phagocytes to migrate out of the blood vessels and to 
the injection site (54). 
 Leakage of fibronectin results in the deposition of fibrin at the site and causes a 
hardened, raised area referred to as an induration. This induration occurs 24 to 48 hours 
after injection, which gives the term delayed type hypersensitivity (54). The induration 
reaches its greatest intensity at 48-72 hours post-injection and regresses rapidly after (45, 
82). The skin thickness at the site of injection is measured immediately before injection 
of PPDb and 72 hours post-injection (6). An animal with any measurable increase in skin 
thickness is considered a reactor and a secondary test is needed. If the animal has no prior 
exposure to M. bovis antigens there is no local inflammatory response and the antigens 
are degraded (31).This DTH responses can develop as early as one week post challenge 
or as late as 9 weeks after challenge (42, 31). The CFT has been demonstrated to have a 
sensitivity and specificity of 80.4-93.0% and 89.2-95.2% respectively (38).  
 A supplementary test that can be used in conjunction with the CFT or on its own is 
the comparative cervical skin test (CCT). The CCT is mainly used as an ancillary serial 
test for CFT reactors or inconclusive reactors within the United States (6, 31). Other 
countries, such as the United Kingdom, use the CCT as a primary test. The CCT uses two 
types of tuberculin, M. avium derived PPD (PPDa) and M. bovis derived PPD (PPDb). 
PPDs are injected separately into the cervical region of the neck (129). Skin thickness at 
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both injection sites are measured before injection and after 72 hours. Responses to the 
two PPDs are plotted on a scattergram and interpreted as positive, negative, or suspect 
(89). The CCT test when used in conjunction with the CFT test has a sensitivity and 
specificity of 74.4-88.4% and 97.3-98.6% respectively (38). However, the sensitivity and 
specificity of each PPD from the same manufacturer can differ from herd to herd (51).  
Current concerns with skin testing include observation-bias depending on the 
visiting veterinarian, false positive reactions due to conserved mycobacterial antigens, 
and time delay between consecutive skin tests (31). False positives in the CFT may occur 
due to exposure to non-pathogenic mycobacterium species encountered in the 
environment, which results in cross-reaction due to conserved antigens (31, 103). It has 
also been demonstrated that repeated testing of a herd can lead to an increase in the 
number of M. bovis infected animals that do not respond to the skin test (48, 58, 67). To 
overcome this effect, skin testing protocols require an interval of at least 42 days (60 days 
after the initial CFT) between skin tests (6). The IFN-γ release assay addresses these 
concerns and only requires one visit to the farm, provides rapid results, and can be 
performed a second time without delay if necessary (122). Pollock and Neill determined 
that infected animals could be detected using the IFN-γ assay even before a DTH 
response developed (81). 
 
IFN-γ release assay  
The IFN-γ release assay has been approved as a supplemental test to the skin test for 
the TB eradication  and control program in the United States. It was first developed in 
1985 in which whole blood was incubated with PPD and plasma supernatants taken after 
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24 hours for examination of IFN-γ production (122).  IFN-γ was chosen because it is 
known to be a robust indicator of a CMI response, particularly to Mycobacterial 
infection. The IFN-γ release assay was first used in large scale field trials in Australia’s 
TB Eradication Program in 1989 and 1990 (122, 123, 113). In diagnosing bovine TB, the 
IFN-γ assay was determined to be significantly more sensitive than the single intradermal 
tuberculin test (SIDT) (123). Wood and colleagues found that out of 125 animals that 
tested culture positive, the IFN-γ assay was able to detect 93.6% of animals whereas the 
SIDT only detected 65.6% of infected animals (123). An increase in sensitivity to 95.2% 
was seen when both tests were used in parallel (123). In 1991 the IFN-γ test was 
implemented as an official diagnostic test for bovine TB in Australia (124). 
The IFN-γ release assay uses PPDa and PPDb (independently in different wells) to 
stimulate lymphocytes within whole blood to produce IFN-γ. Quantification of IFN-γ 
production is measured using an by ELISA after incubation overnight with 
mycobacterium specific antigens. Responses are deemed positive when IFN-γ from PPDb 
stimulation is greater than that of PPDa stimulation (e.g., an optical density (OD) higher 
than 0.1 (PPDb-PPDa) at a wavelength of 450 nanometers once the nil antigen (i.e. 
control) is subtracted). The EIA can also measure false positive reactions, which are 
indicated by a greater production of IFN-γ to PPDa than to PPDb (55).  When used in 
parallel with the intradermal skin test, the IFN-γ release assay can increase overall 
disease detection sensitivity (83). With the variety of IFN-γ assay protocols, the accuracy 
of the tests has a sensitivity and specificity of 80.9-100% and 87.7- 99.2% respectively 
(93). IFN-γ responses can be detected as early as 14 days after challenge with M. bovis 
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(13, 32). It has also been reported that the IFN-γ assay can identify infection 90 to 150 
days earlier then the skin test (60, 69).  
Although it is costly to perform, the IFN-γ release assay results in overall cost 
savings by removing the necessity of holding of cattle for testing, veterinary fees, and 
time delays due to retesting (125). In addition, unlike the CFT and CCT, the IFN-γ 
response is not reduced by multiple tuberculin skin tests thereby reducing time between 
testing (33, 85). 
The skin test and the IFN-γ release assays are very important in the detection of 
bovine TB and improvement of their diagnostic capabilities is needed. Using only PPDs 
in both the skin test and IFN-γ assay is not effective in differentiating BCG vaccination 
from active infection due to response elicited to conserved antigens (14, 114). With the 
advent of genome sequencing, it was found that M. bovis BCG is missing a region of 
genomic DNA, referred to as region of difference 1 (RD1), which is present in M. bovis 
and most other Mtbc species (73). This has led to the identification and isolation of 
proteins encoded within the RD1 as a means to differentiate BCG vaccination from M. 
bovis infection (114). 
 
Improvements of ante-mortem tests through identification and use of Mtbc-specific 
proteins 
 In bovine TB control and eradication, the ideal ante-mortem test would have the 
ability to differentiate vaccinated and infected cattle (DIVA) (114). This would enable 
routine vaccination as a means of protection while allowing the detection of infection 
without false test results due to responses to conserved antigens. Target antigens for 
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DIVA tests are those that are present in M. bovis, but absent in BCG or other species of 
environmental mycobacteria (10, 50, 114). Vordermeier and colleagues have separated 
current potential DIVA reagents into two categories; antigens encoded on gene regions 
that were deleted from the BCG genome and antigens discovered through comparative 
transcriptome analysis (114).  
 Currently, the two main antigenic targets for both cattle and humans most commonly 
used in TB diagnostic assays are Early Secretory Target Antigen 6 (ESAT-6, Rv3875) 
and Culture Filtrate Protein 10 (CFP-10, Rv3874) (1, 11, 79). Both ESAT-6 and CFP-10 
were identified using direct genome comparisons of M. bovis BCG and virulent M. bovis 
strains (11, 79). Genes encoding both ESAT-6 and CFP-10 are found in the RD1 region 
(46, 63) which enables differentiation of BCG vaccination status from active TB in both 
humans and cattle (68, 111, 114, 116). ESAT-6 and CFP-10 are co-secreted proteins that 
play a role in escape from the phagolysosome and produced during the early phase of 
infection (117). This allows for the early detection of immune responses by diagnostic 
assays (108). ESAT-6 is often used as a fusion protein or in a peptide cocktail with CFP-
10 to increase test sensitivity and specificity of the IFN-γ assay (80, 111. 113, 115). 
Pollock and colleagues demonstrated that the fusion protein of ESAT-6 and CFP-10 
could increase the sensitivity and specificity of the IFN-γ assay to 76.3% and 99.2% 
respectively (80). Additionally, in naturally infected cattle, it was found that peptide 
cocktails containing a mixture of peptides derived from the amino acid codes of ESAT-6 
and CFP-10 could be used in place of recombinant proteins with comparable efficacy 
(111). Vordermeier and colleagues further demonstrated that BCG vaccinated animals 
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did not respond to the peptide cocktail of ESAT-6 and CFP-10 whereas 70% responded 
to bovine tuberculin using the IFN-γ assay (111). 
The ability to identify  peptide pools by genetic comparison and analysis has allowed 
researchers to combine peptides from various regions of virulent M. bovis genomes into 
cocktails to improve diagnostic sensitivity(20, 21, 56). Cockle and colleagues evaluated 
28 potential antigens encoded on the RDs absent from BCG Pasteur, (RD1, RD2, and 
RD14), but present in virulent M. bovis for immunogenecity (20). They further compared 
synthesized peptide pools of two proteins from RD1, Rv3873 and Rv3879c, and two 
ESAT-6 like proteins, Rv0288 (TB10.4), and Rv2019c based on their ability to elicit a 
robust IFN-γ response (21, 98). They then selected the sequences from the peptide pools 
with the most robust IFN-γ responses to incorporate into a peptide cocktail with ESAT-6 
and CFP-10 (21). Although they did not investigate DIVA potential, they did find that the 
addition of these peptide sequences to a peptide cocktail with ESAT-6 and CFP-10 
enhanced the sensitivity of the assay to diagnose infection in animals missed by skin 
testing (21, 114). 
Comparative transcriptomics has allowed scientists to assess the transcriptomes of 
M. bovis BCG and virulent M. bovis after the infection of macrophages using genome 
data and DNA microarrays (114). This has allowed the quantification and comparison in 
the level of gene expression between the two strains (56, 95, 114). Sidders and colleagues 
refer to the increased expression of genes as the ‘abundant invariome’ (95). The abundant 
invariome consists of a population of gene products that were expressed at high levels by 
virulent M. bovis, but not M. bovis BCG under various culture conditions (56, 95).  One 
member of this group was Rv3615c. Sidders and colleagues demonstrated that when 
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incorporated into the IFN-γ release assay, Rv3615c was able to differentiate M. bovis-
infected cattle from BCG vaccinated cattle (96). They also noted that some animals that 
did not have responses to the peptide cocktail containing ESAT-6 and CFP-10 yet 
responded to Rv3615c which suggested the target antigens were identified through 
different mechanisms (56, 96). In the IFN-γ assay, incorporating Rv3615c into a peptide 
cocktail with ESAT-6 and CFP-10 resulted in increased sensitivity without a loss in 
specificity (114, 119). When used in the single comparative cervical intradermal skin test 
(SICCT), the response to a protein cocktail consisting of Rv3615c, ESAT-6, and CFP-10 
were comparable to those elicited by bovine PPD (17). Jones and colleagues screened 
119 secreted, or potentially secreted, proteins that could serve as a DIVA reagent for the 
IFN-γ assay (56). They found three potential pools, Rv2346c, Rv3020c, and Sec2 (which 
consisted of a cocktail of nine peptides derived from multiple antigens) (56). Although 
the Rv2346c and Rv3020c sequences were present in both the BCG and M. bovis 
genome, it is thought that the gene transcription of these two proteins may vary between 
BCG and virulent M. bovis (56, 88).  
Jones and colleagues further demonstrated that the incorporation of both Rv2346c 
and Rv3020c into a peptide cocktail with ESAT-6, CFP-10, and Rv3615c resulted in 
increased sensitivity and comparable specificity as bovine PPD when used in the SICCT 
as well as the ability to perform as a DIVA reagent (57). Evaluations using this peptide 
cockatil in the IFN-γ assay were inconclusive as animals were under 6 months of age and 
therefore had non-specific IFN-γ responses that interfered with the ability to differentiate 
responses (57). Other proteins that are present in both M. bovis BCG and virulent M. 
bovis that have potential as DIVA reagents are M. bovis protein 70 (MPB70), and MPB83 
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(18, 126). It has been demonstrated previously, using an antibody-capture ELISA, that 
MPB70 and MPB83 have a high specificity in detecting infection, but a low sensitivity 
(62, 126). When MPB70 and MPB83 proteins were tested individually and in 
combination with ESAT-6 and CFP-10 using the IFN-γ assay and skin test, there was a 
decrease in both sensitivity and specificity when compared to bovine PPD using naturally 
infected animals (120).  
Overall, the consensus is the same; a cocktail of defined immune-dominant peptides 
can result in a novel diagnostic reagent that has the ability to detect M. bovis-infected 
animals that were deemed negative by skin tests (21, 56, 96, 114).  
 
Incorporation of Mtbc specific antigens and evaluation of PPDs in the IFN-γ release 
assay 
 Incorporation of M. bovis-specific antigens has the potential to increase the 
diagnostic accuracy of the IFN-γ release assay (21) and may provide DIVA capacity 
(114). The IFN-γ assay is rapid to perform, has increased sensitivity compared to the skin 
test, and minimizes observational variability associated with assessing skin test reactions 
(31, 92, 113). However, BCG vaccination has been found to compromise the specificity 
of the tuberculin in the IFN-γ tests (13, 14,110, 114). The IFN-γ assay is an ideal means 
to DIVA since it can be readily modified to accommodate various antigens unlike the 
tuberculin skin test (114). When DIVA reagents were incorporated into the skin test, it 
was found to require an impractical amount of recombinant proteins (81) and the 
inclusion of adjuvants to induce measurable responses (119, 114). By incorporating them 
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into the IFN-γ assay, the need for large amounts of Mtbc-specific antigens is generally 
not necessary (114).  
The standard use of the IFN-γ assay is performed using whole blood that is stimulated 
for 16-24 hours with PPDa, PPDb, media alone (no stimulation), and a mitogen control 
for cell viability. IFN-γ produced within the stimulated samples is then measured by an 
ELISA. Infection status is determined by subtracting the no stimulation response from all 
other responses and then measuring the differential amounts of IFN-γ produced in 
response to PPDb versus PPDa. Currently, there are several PPDs on the market for IFN-
γ release assays. 
PPDs from different manufacturers and lots are known to vary in potency (92). PPDs 
undergo different production processes, which causes this variation (8, 15, 48).  Whipple 
and colleagues compared Commonwealth Serum Laboratory (CSL, New Zealand) PPDs 
to those produced by the United States (US) Animal and Plant Health Inspection Service 
using both the skin test and IFN-γ assay (121). They found that both CSL and US PPDs 
were able to detect M. bovis-infected and non-infected animals, but US PPDs elicited a 
higher response (121). Similarly, Downs and colleagues reviewed data from field 
surveillance results of SICCT using Prionics (Lelystad) PPD and Central Veterinary 
Laboratory (Weybridge) PPD (2013). The compilation and analysis of the surveillance 
results revealed that Lelystad PPDs were superior to Weybridge PPDs in confirming 
infection within herds and individual animals using the SICCT (35). These studies 
demonstrate the differences between PPDs and the effect it can have on detecting 
infected cattle using ante-mortem testing. In order to improve diagnostic accuracy, 
20 
 
evaluation of PPDs from different manufacturers needs to be examined before 
incorporation into ante-mortem testing. 
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CHAPTER 2:  Comparison of Peptide Cocktails and Purified Protein Derivatives 
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Abstract 
 Currently the Bovigam assay is used as an official supplemental test within the 
bovine tuberculosis eradication program. This assay measures interferon-gamma (IFN-γ) 
produced by lymphocytes in response to specific antigens. The objectives of the present 
study were to evaluate two Mycobacterium bovis specific peptide cocktails, purified 
protein derivatives (PPDs) from two sources, liquid and lyophilized antigen preparations, 
and a second generation IFN-γ release assay (Bovigam, B2G, Prionics AG). Three strains 
of M. bovis were used for experimental challenge: M. bovis 95-1315, M. bovis Ravenel, 
and M. bovis 10-7428. Additionally, samples from tuberculosis-affected herds (i.e. 
natural infection) were evaluated. Robust responses to both peptide cocktails HP (PC-HP) 
and ESAT6/CFP10 (PC-EC), as well as PPDs were elicited as early as three weeks after 
challenge. Only minor differences in responses to Commonwealth Serum Laboratories 
(CSL) and Lelystad PPDs were detected with samples from experimentally infected 
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animals. For instance, responses to Lelystad M. avium derived PPD (PPDa) exceeded 
respective response to CSL PPDa in M. bovis Ravenel infected and control animals. 
However, 1:4 dilution of stimulated plasma demonstrated greater separation of PPDb 
from PPDa responses (i.e., PPDb – PPDa) with use of Lelystad PPDs, suggesting that 
Lelystad PPDs provide greater diagnostic sensitivity than CSL PPDs. With samples from 
tuberculosis-affected herds, responses to Lelystad PPDs generally exceeded respective 
responses to CSL PPDs. Responses to lyophilized and liquid antigen preparations did not 
differ. Responses detected with first (B1G) and second (B2G) generation IFN-γ release 
assay kits (Bovigam) did not differ throughout the study. In conclusion, antigens may be 
stored in a lyophilized state without a loss in potency; PC-HP and PC-EC are dependable 
biomarkers for aiding diagnosis of bovine tuberculosis, and second generation Bovigam 
kits have sensitivity/specificity comparable to current kits. 
Introduction 
Mycobacterium bovis is the primary causative agent of bovine tuberculosis in 
cattle. M. bovis is a member of the Mycobacterium tuberculosis complex (Mtbc), which 
also includes M. tuberculosis, M. caprae, M. microti, M. africanum, M. canettii, and M. 
pinnipedii (1). Mtbc species are similar to one another in their ability to cause 
tuberculosis infections; however, their host range varies as well as their virulence 
between hosts. M. bovis has the largest host range of the Mtbc species infecting wildlife 
as well as alternative and domestic livestock making it difficult to control (2). In many 
developed countries, cattle herds are monitored for bovine tuberculosis using 
slaughterhouse surveillance and ante-mortem testing. Ante-mortem testing is primarily 
based upon measures of cell-mediated immunity such as tuberculin skin test (e.g. caudal 
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fold test (CFT) or single intradermal comparative cervical (SICCT)) and interferon-
gamma (IFN- γ) release assays (e.g., Bovigam, Prionics AG, Schlieren, Switzerland) (3). 
In countries where annual skin testing is largely absent, such as tuberculosis-free states 
within the United States, most infected cattle go unnoticed until a lesioned animal is 
detected by slaughterhouse surveillance (4). After infection is detected, the movement 
history is investigated to determine other contact herds and the origin of infection (3). 
Affected herds may be depopulated or a test and slaughter approach is applied using skin 
test and/or the IFN-γ release assay. Additionally, emerging serologic tests (i.e. antibody 
based tests) are being evaluated for use in tuberculosis control programs. Although these 
tests are relatively accurate, improvement of ante-mortem diagnostic methods is needed. 
The IFN-γ release assay was developed to aid in the diagnosis of bovine 
tuberculosis and is currently used mainly as a supplemental assay to the skin test in most 
TB eradication/control programs. IFN-γ is produced in high quantities in vitro and is not 
readily consumed during short-term culture (5, 6) making it a good biomarker for use in 
tuberculosis diagnostic tests (7). The standard use of the IFN-γ assay is performed by 
stimulating whole blood for 16 to 24 hours with M. bovis purified protein derivative 
(PPDb), M. avium PPD (PPDa), media alone (no stimulation), and a mitogen control for 
cell viability (6). IFN-γ produced within the stimulated samples is then measured by 
ELISA.  Infection status is determined by comparing differential amounts of IFN-γ 
produced in response to PPDb and PPDa stimulation.  
When compared to the skin test, the IFN-γ assay has increased sensitivity, 
requires a single visit to the farm, and prevents observational variability associated with 
assessing skin test reactions (8, 3, 9). With the use of PPDs, the sensitivity and specificity 
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of the IFN-γ assay is estimated at 73-100%, and 87.7-99.2%, respectively (4,9). 
Implementing TB-specific antigens into the IFN-γ assay may increase the accuracy of the 
test (10) and may provide differentiation of infected from vaccinated animals (DIVA) 
(11). Early Secretory Antigen Target 6 (ESAT-6) and Culture Filtrate Protein 10 (CFP10) 
are TB-specific proteins that have been extensively studied for use in the detection of 
bovine tuberculosis (12, 13, 10, 14). When used as recombinant proteins or peptide 
cocktails, ESAT6 and CFP10 are known to elicit an immune response; both in vitro (13, 
15, 14) and in vivo (16), in M. bovis infected cattle. Aagaard and colleagues (10) 
demonstrated decreased sensitivity (86% vs. 97%) yet increased specificity (99% vs. 
94%) when comparing an ESAT6 and CFP10 peptide cocktail versus PPDs as antigens 
for use in the IFN-γ assay. This increased specificity elicited by the ESAT6 and CFP10 
peptide cocktail is promising; however, more research is needed to determine methods to 
increase sensitivity (17). For instance, use of ESAT6 and CFP10 in combination with 
Rv3615 in the IFN-γ assay has been shown to increase sensitivity without loss of 
specificity (18).  
Objectives of the current study were to compare IFN-γ responses elicited by 
Commonwealth Serum Laboratories (CSL) and Lelystad PPDs (Prionics AG), two Mtbc-
specific peptide cocktails, as well as liquid and lyophilized preparations. Studies were 
performed using samples from three groups of cattle, each experimentally infected with a 
different strain of M. bovis, as well as samples from tuberculosis-affected herds (i.e. 
natural infection) within the United States. Strains for experimental infection included: 
M. bovis Ravenel (laboratory adapted strain attenuated in cattle), M. bovis 95-1315 
(white-tailed deer isolate), and M. bovis 10-7428 (cattle field isolate from a Colorado 
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dairy herd). PPDs and peptide cocktails were also used to compare a second-generation 
Bovigam kit to the currently available kit. 
Materials and Methods 
Calves, aerosol challenge, and necropsy 
For the first study, 15 nine-month old Holstein castrated male cattle were housed 
in a BSL-3 containment facility in Ames, IA at the National Animal Disease Center.  All 
animal care and use procedures were reviewed and approved by the NADC Animal Care 
and Use Committee. Treatment groups included M. bovis 95-1315 inoculated cattle (10
5 
cfu, n=5), M. bovis Ravenel (10
5 
cfu, n=5, ATCC strain 35720, kind gift from John Chan, 
Albert Einstein College of Medicine, NY) inoculated cattle, and a non-infected control 
group (n=5). For the second study, 23 six month old Holstein castrated male cattle were 
housed as above. Treatment groups included M. bovis 95-1315 (5 x 10
4
 cfu, n=8), M. 
bovis 10-7428 (5 x 10
4
 cfu, n=8), and a non-infected control group (n=7).  Strains were 
prepared using standard procedures (19) in Middlebrook 7H9 liquid media (Becton 
Dickinson, Franklin Lakes, NJ) supplemented with 10% oleic acid-albumin-dextrose 
complex (OADC) plus 0.05% Tween 80 (0.5% Glycerol included for strain Ravenel 
only). Enumeration of M. bovis challenge inocula, necropsy procedures (~3.5 months 
after challenges) gross and microscopic assessment of lesions, as well as mycobacterial 
culture of M. bovis from tissues were performed as described (20, 15). The inoculation of 
each of the strains in both studies was via aerosol as described (20). Additionally, whole 
blood samples were obtained from TB-affected herds in California (2 separate herds), 
Colorado (1 herd), and Washington (1 herd). 
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Antigens 
PPDs and peptide cocktails were provided by Prionics AG (Schlieren, 
Switzerland) in liquid and lyophilized forms. RPMI 1640 medium (Life technologies, 
Grand Island, NY) was used as a negative control and pokeweed mitogen (PWM, 5ug/ml; 
Sigma-Aldrich, St. Louis, MO) was included as a positive control of cell viability. The 
two peptide cocktails consisted of ESAT-6 and CFP10 (PC-EC, Prionics AG) and 
ESAT6, CFP10, Rv3615, and three other mycobacterium antigens (PC-HP, Prionics AG). 
Aliquots of liquid preparations of PC-HP and PC-EC were kept frozen at -20°C until the 
day of use. PC-HP and PC-EC were used according to insert instructions. CSL PPDa and 
CSL PPDb were used at a concentration of 20ug/ml and Lelystad PPDa and Lelystad 
PPDb at 200IU and 250IU, as recommended by the manufacturer. All antigens were 
diluted in RPMI 1640 medium.  
Whole blood stimulation  
For the first study, whole blood was collected in sodium-heparinized tubes two 
week prior to aerosol challenge and at 3, 6, 8, 11, and 12 weeks post-challenge. On the 
day of blood collection 250μl of blood was added to 96-well plates from each animal. 
Twenty-five microliters of each antigen (PPDs and peptide cocktails) and controls (e.g. 
RPMI 1640 and PWM) were added in duplicate to selected wells. Plates were incubated 
at 39°C with 5% CO2 for 18-22 hours. Plasma was harvested from each stimulation for 
each animal, and placed in individual microtubes (VWR Scientific, Radnor, PA) and 
stored at -80°C until analyzed for detection of IFN-γ via the Bovigam assay.  For the 
second study, blood was collected at 2 weeks pre challenge as well as 2, 3, 4, 6, 8, and 12 
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weeks post-challenge. Whole-blood stimulation procedures were the same as the first 
study.  
IFN-γ detection  
In the first study, IFN-γ assays were performed using the first generation 
Bovigam kit (Prionics AG). In the second study, first and second generation Bovigam 
kits were used. All IFN-γ release assays were performed according to kit procedures. 
Each plasma sample and standard was tested in duplicate. Recombinant bovine IFN- γ 
(Thermo Scientific, Rockford, IL) was used as a standard at 12.5 ng/ml, 6.25 ng/ml, 
5ng/ml, 2.5 ng/ml, 1.25 ng/ml, 0.625 ng/ml, and 0.3125 ng/ml, along with the positive 
and negative controls supplied by the manufacturer. Samples were read at a wavelength 
of 450nm using a SPECTRAmax 340 microplate reader (Molecular Devices, Sunnyvale, 
CA) and analyzed using SOFTmax PRO software (Molecular Devices, Sunnyvale, CA) 
to calculate optical density (OD). Responses to negative control (RPMI 1640) for each 
animal were subtracted from all antigen and mitogen responses. Results were considered 
positive if responses to PPDb (OD450) minus PPDa (OD450) were above 0.1OD. 
Tuberculin skin test procedures  
Skin tests were performed as specified in the circular on uniform methods and 
rules for the eradication of bovine tuberculosis in the United States (Animal and Plant 
Health Inspection Service, APHIS circular 91-45-011) (21). At 10 weeks (study 1) or 12 
weeks (study 2) post-challenge, skin thickness was measured with calipers immediately 
before intradermal injection of PPDa and PPDb. The skin thickness was measured again 
after 72 hours. The skin test was performed in the mid-cervical region (i.e, comparative 
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cervical test). Responses were recorded on a scattergram for interpretation of comparative 
cervical test to determine the outcome of the test (i.e., negative, suspect or reactor). 
Cattle pathogenesis studies: bacterial recovery and assessment of lesions  
All calves were euthanized ~3.5 months after challenge by intravenous 
administration of sodium pentobarbital. Tissues were observed for gross lesions and 
collected and processed for microscopic analysis and isolation of M. bovis. Tissues 
collected included: palatine tonsil; lung; liver; and mandibular, parotid, medial 
retropharyngeal, mediastinal, tracheobronchial, hepatic, and mesenteric lymph nodes. 
Lymph nodes were sectioned at 0.5 cm intervals and examined. Each lung lobe was 
sectioned at 0.5 – 1.0 cm intervals and examined separately.  
Tissues collected for microscopic analysis were fixed by immersion in 10% 
neutral buffered formalin. For microscopic examination, formalin-fixed tissues were 
processed by standard paraffin-embedment techniques, cut in 5 μm sections and stained 
with hematoxylin and eosin. Adjacent sections from samples containing caseonecrotic 
granulomata suggestive of tuberculosis were excised and stained by the Ziehl-Neelsen 
technique for identification of acid-fast bacteria. 
Isolation of Mycobacterium bovis from cattle tissues were as described (22). 
Briefly, tissues were macerated in phenol red nutrient broth using a blender (Oster, 
Shelton, CT). Homogenates were decontaminated with NaOH, and then neutralized with 
HCl. Samples were centrifuged, supernatant removed, and pellet used to inoculate media 
(Middlebrook 7H10, 7H11, and 7H11 with antibiotics). Plates were incubated at 37°C 
and examined weekly for growth.   
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Statistics  
Results were analyzed using Graph Pad Prism (Software, La Jolla, CA). Optical densities 
were converted to ng/ml using the standard curve calculated from standards observed on 
each plate for each date. Data were analyzed using repeated measures analysis of 
variances with Bonferroni multiple comparisons test and Mann-Whitney T test. 
Results 
Experimental infection  
Ten to 12 wks after challenge, all cattle receiving M. bovis, regardless of strain 
(i.e., Ravenel, 95-1315, 10-7428), were classified as reactors based upon standard 
interpretation of the comparative cervical skin test. Delayed type hypersensitivity 
responses were not detected (i.e., classified as negative) with any of the animals within 
the non-infected control group. Upon necropsy, only one M. bovis Ravenel-inoculated 
calf had a single small granuloma in the left caudal lung lobe. In contrast, all M. bovis 95-
1315- and M. bovis 10-7428-inoculated cattle had granulomatous lesions in lungs and 
lung-associated lymph nodes. M. bovis was isolated from 4 of the 5 cattle inoculated with 
M. bovis Ravenel and all cattle receiving M. bovis 95-1315- or M. bovis 10-7428. M. 
bovis was not isolated from cattle within the non-infected group. Findings are consistent 
with the observation that M. bovis Ravenel is attenuated in cattle (Waters / Palmer, 
personal observations) and M. bovis strains 95-1315 and 10-7428 are fully virulent.  
Comparison of liquid and lyophilized antigen preparations  
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IFN-γ responses to liquid and lyophilized preparations were detected in M. bovis 95-1315 
and M. bovis Ravenel inoculated animals as early as three weeks after challenge (Fig. 1, 
P < 0.05). When all time points were pooled, responses to liquid and lyophilized antigen 
preparations by M.bovis Ravenel and M. bovis 95-1315 challenged animals to PPDb, PC-
HP, and PC-EC exceeded (P < 0.05) respective responses by control animals (Fig. 1b). 
Significant differences were not detected  between liquid and lyophilized products for 
any antigens within each treatment group (Fig. 1b). As utilized for official use of the 
Bovigam test kit, responses to PPDb-PPDa did not differ (P > 0.05) for liquid and 
lyophilized antigen preparations at any time point within each treatment group (Fig. 1c). 
 IFN-γ responses to PPDa exceeded (P < 0.01) respective responses to PPDb for 
control animals (Fig. 1b), demonstrating prior sensitization to non-tuberculous 
mycobacteria (NTM).  Responses to Mtbc-specific antigens (PC-HP and PC-EC) were 
not detectable prior to challenge (Fig. 2a), and subtraction of PPDa responses from PPDb 
(PPDb-  animals prior to 
challenge (Fig. 1c). Thus, responses to PPDb detected prior to challenge in all groups 
(Fig 1a) were likely due to cross-reactive responses elicited by NTM.  
Evaluation of peptide cocktails for the detection of bovine tuberculosis 
  As early as three weeks after challenge, responses to PC-HP and PC-EC by M. 
bovis Ravenel and M. bovis 95-1315 inoculated animals exceeded (P < 0.05) respective 
pre-challenge responses and responses by control animals (Fig. 2a). When all time points 
were pooled, there was no difference (P > 0.05) between responses to PC-HP and PC-EC 
within treatment groups (Fig. 2b).  Similar responses were detected in the second study 
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using M. bovis 95-1315 and M. bovis 10-7428 challenged animals, and responses to PC-
HP and PC-EC did not differ within treatment groups (Supplemental Fig 1). These 
findings demonstrate that responses to PC-HP and PC-EC are equivalent for the early 
detection of M. bovis infection in cattle. 
Comparison of IFN-γ responses to Lelystad and CSL PPDs in experimentally and 
naturally infected animals  
Lelystad and CSL PPDs are commonly used as antigens in the Bovigam assay for 
the detection of M. bovis infection in cattle (23, 24); however use of these antigens within 
IFN-γ release assays have yet to be directly compared. Experimental infection with M. 
bovis Ravenel, M. bovis 95-1315, and M. bovis 10-7428 elicited robust IFN-γ responses 
to both CSL and Leylstad PPDs (Fig. 3 and Supplemental Fig. 2). When pooled over 
time, responses to Lelystad PPDa exceeded (P < 0.05) responses to CSL PPDa within the 
control and M. bovis Ravenel treatment groups (Fig. 3a). Similarly, responses to Lelystad 
PPDb exceeded (P < 0.05) that of CSL PPDb in control animals when pooled (Fig 3a).  
Experimental infection of cattle with M. bovis results in robust IFN-γ responses to 
both PPDb and PPDa (due to cross-reactivity of antigens) that are often at the maximum 
detection limit of the assay; thereby limiting the comparisons of PPD potencies and 
diagnostic potential. Thus, several dilutions of stimulated plasma were evaluated at select 
time points to further evaluate the kinetics of the response and potency comparison of the 
two PPDs (Table 1, Fig. 4). When plasma from experimentally-infected animals was 
diluted, it was determined that the majority of responses after challenge to PPDa were 
lower than the response to PPDb, giving a difference greater than 0.1 OD450 indicating a 
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positive test result (Table 1, Fig 4). When diluted, responses to Lelystad PPDb-PPDa 
exceeded (P < 0.05) responses to CSL PPDb-a respectively (Figure 4). In general, 
diluting the plasma enabled accurate detection of M. bovis infection in experimentally-
infected animals in addition to reducing the false positive test results within the control 
group. 
To further compare CSL and Lelystad PPDs, samples were obtained from four 
tuberculosis affected dairy herds (California herd 1, n=710; California herd 2, n=78; 
Washington, n=11; Colorado, n=126) in the United States. All animals were considered 
tuberculosis-exposed, as cattle that were positive by skin test had been removed from 
each of the herds, excluding the Colorado herd that included both tuberculosis-exposed 
and -infected animals. In contrast to experimental infection studies in which samples 
were placed in culture with antigen within two hours of blood collection, samples from 
naturally exposed animals were shipped overnight and set up within 20 hours of blood 
collection. With samples from California and Washington, responses to Lelystad PPDa 
exceeded (P < 0.01) that of CSL PPDa, and responses to CSL PPDb exceeded (P < 0.01) 
that of Lelystad PPDb (Fig. 5 a). Also with PPDb-PPDa calculations, CSL exceeded (P < 
0.01) that of Lelystad (Fig. 5 a). With samples from the Colorado dairy, responses to 
Lelystad PPDs exceeded (P < 0.01) those to CSL PPDs, including PPDb-a (Fig. 5b) 
Performance of second-generation Bovigam kits (B2G) in comparison to the currently 
licensed kit (B1G).  
B1G and B2G kits were compared using experimentally infected animals (Fig. 6). 
IFN-γ responses were not different (P > 0.05) between the two kits when time points 
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were pooled (Fig. 6a). B2G kits were just as effective in the differentiation of control and 
infected groups when PPDb-PPDa calculations were performed throughout the course of 
the study (Fig 6 b,c,d). 
Discussion 
IFN-γ is a reliable biomarker for use in the detection of M. bovis infection. With 
the current use of the Bovigam assay, antigens are provided within the kit as a liquid 
preparation. In this study, lyophilization had no effect on antigen performance. Responses 
were detected as early as three weeks post-challenge with both liquid and lyophilized 
antigen preparations. These findings indicate that lyophilized preparations may be 
implemented into the IFN-γ assay without loss in potency, which could potentially 
increase the shelf-life of the test kits. Additional TB-specific antigens are needed to 
further increase the accuracy of the IFN-γ release assay. In experimentally infected 
animals, responses to PC-HP and PC-EC were detectable as early as three weeks post-
challenge. PC-HP and PC-EC are commercially available products that may prove useful 
as antigens for bovine tuberculosis test kits, both for research and diagnostic purposes. 
PPDs from differing manufacturers and lots are known to vary in potency (8). 
Commonwealth Serum Laboratories (CSL) has been the producer of PPDs for the 
Bovigam assay since the test was first approved for use in the United States. Due to 
manufacturing and marketing reasons, it is possible that CSL PPDs will not be available 
in the near future. Thus, it is critical to validate use of different PPDs within bovine 
tuberculosis diagnostic tests. Whipple and colleagues performed direct comparisons 
between CSL PPDs and PPDs prepared in the United States (USDA, APHIS, National 
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Veterinary Services Laboratory) using the CFT and IFN-γ assay and found the final 
interpretation of the test (i.e. positive and negative animals identified by each PPD) was 
usually the same. However, United States PPDs elicited a higher response (25). Recently 
Lelystad (Prionics AG) was adopted for use in the skin test and Bovigam assay in the 
United Kingdom, Republic of Ireland, and various other European Union countries. 
Downs and colleagues reviewed data from field surveillance results of single intradermal 
comparative cervical skin test (SICCT) using Lelystad and Weybridge (Central 
Veterinary Laboratory) PPDs in England, Scotland, and Wales from 2005 to 2009 (26). 
Due to financial reasons, Defra halted production of tuberculin at Weybridge and their 
tuberculin supply was exhausted in 2009 (26). Lelystad became the sole source of 
tuberculin in Great Britain; however, there was no data directly comparing the two 
sources of PPDs. Compilation and analysis of field surveillance results determined that 
Lelystad PPDs were superior to Weybridge PPDs in confirming infection within herds 
and individual animals using the SICCT (26). Lelystad has been used in IFN-γ release 
assays since 2007 (27); however, direct comparison to CSL PPDs has not been 
performed. In the present study, IFN-γ responses to Lelystad and CSL PPDs largely did 
not differ in un-diluted samples from experimentally infected cattle. (Fig. 3 and 
Supplemental Fig. 2).  However, use of diluted sera (1:4) revealed greater differentiation 
of PPDb from PPDa responses (i.e., PPDb-PPDa, Fig. 4) elicited after experimental M. 
bovis infection.With samples from tuberculosis-affected herds, responses to Lelystad 
PPDs generally exceeded respective responses to CSL PPDs.   
Experimental infection of cattle resulted in IFN-γ responses to both PPDb and 
PPDa that reached the maximum limit of detection resulting in a PPDb-PPDa responses 
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of less than 0.1 ΔOD (i.e. negative) even though these animals were clearly infected as 
evidenced by robust IFN-γ responses to Mtbc peptide cocktails, delayed type 
hypersensitivity responses to PPDb exceeding that of PPDa, and isolation of M. bovis 
from tissues at necropsy. Thus, differences between control and infected animals were 
not detectable using the PPDb-PPDa analysis with undiluted stimulated plasma. To 
address this issue, dilutions of plasma were evaluated to ascertain IFN-γ concentrations 
detectable within assay limits. After dilution (1:4), samples from infected animals had 
responses to PPDb that exceeded (p < 0.05) respective responses to PPDa, thus enabling 
an accurate diagnosis using PPDb-PPDa calculations. Dilution of plasma may be 
incorporated as a means to determine differences in IFN-γ responses to PPDb and PPDa. 
This may be particularly useful in regions where detection of bovine tuberculosis is 
hindered by high levels of exposure to NTM that elicit cross-reactive responses to PPDs. 
Additionally, evaluation of diluted samples may be useful when evaluating responses by 
animals with very robust responses as seen with experimentally-infected animals in this 
study. Indeed, use of diluted plasma revealed responses to Lelystad PPDs exceeding that 
of CSL PPDs with samples from experimentally-infected cattle. These findings suggest 
that use of Lelystad PPDs will provide increased diagnostic sensitivity than CSL PPDs. 
In the current study, three strains of M. bovis were used to compare IFN-γ 
responses to PPDs and peptide cocktails elicited after experimental infection. Using the 
IFN-γ release assay, robust responses were detected using PPDs from the two different 
manufacturers as well as PC-HP and PC-EC.  Strains examined were M. bovis 95-1315 
(white-tailed deer field isolate), M. bovis Ravenel (laboratory adapted strain) and M. 
bovis 10-7428 (cattle field isolate from a Colorado dairy). M. bovis strain 95-1315 has 
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been used previously in experimental infection of cattle and has been shown to elicit 
robust immune responses as well as granulomatous lesions at necropsy (15). M. bovis 
strain Ravenel was isolated in the early 1900s and although it is virulent in mice (28), 
rabbits (29; 28), and guinea pigs (30; 28; 13), it does not lead to progressive disease in 
cattle (Waters and Palmer, unpublished observations). These findings demonstrate that 
M. bovis Ravenel is attenuated in cattle. M. bovis strain 10-7428 was isolated from a 
Holstein cow in a dairy herd in Colorado. This strain is speculated to be highly virulent 
given the rapid rate of progression of disease in this herd (Tolani Francisco, personal 
communication). In the present study, all M. bovis 95-1315 animals had granulomatous 
lesions, whereas only one M. bovis Ravenel animal had a small tuberculous lesion. In the 
second study, all animals in the M. bovis 95-1315 and M. bovis 10-7428 groups showed 
lesions upon necropsy as well as robust skin test responses. Thus, evaluation of IFN-γ 
responses to various antigen preparations were evaluated with samples from animals 
inoculated with 3 different strains of varying virulence.   
PPDs and peptide cocktails were also used for comparison of two generations of 
Bovigam kits. The second generation kit has a decreased number of repeated washes and 
combined the conjugate and chromogen into one solution; however, stimulation and 
incubation times within the test did not change. Although the new kit did not decrease the 
performance time, it did reduce the time in work labor. Present findings support the use 
of the second generation Bovigam kit (B2G) for replacement of the current kit (B1G) in 
the detection of bovine tuberculosis. 
 In conclusion, lyophilized PPDs, PC-EC, and PC-HP are an effective replacement 
of liquid antigens for use in the Bovigam assay. PC-HP and PC-EC are reliable 
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biomarkers of bovine tuberculosis and second generation Bovigam kits perform similarly 
as first generation kits. Present findings, while not definitive, are encouraging for 
replacement of CSL PPDs with Lelystad PPDs for use in the Bovigam assay for the 
detection of bovine tuberculosis. These findings, along with future evaluation of naturally 
infected animals, have the potential to increase the accuracy of current ante-mortem 
diagnostic methods in the detection of bovine tuberculosis. 
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Figure 1: Comparison of IFN- γ responses to liquid and lyophilized antigen preparations 
from control (n=5), as well as M. bovis Ravenel (n=5), and M. bovis 95-1315-infected 
(n=5) animals. a) Response kinetics: PPDb minus no stimulation. b) Liquid and 
lyophilized antigen preparations pooled over time. c) Response kinetics: PPDb-PPDa. 
Responses to pokeweed mitogen (PWM) are included as a positive control for cell 
viability. 
53 
 
 
Figure 2: Comparison of IFN-γ responses to PC-HP and PC-EC in control (n=5) as well 
as, M. bovis Ravenel (n=5), and M. bovis 95-1315 infected animals. a) Responses over 
time b) Pooled over time. 
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Figure 3: IFN- γ responses upon experimental infection with M. bovis to CSL 
(Commonwealth Serum Laboratory) and Lelystad (LEL) PPDs. a) Comparison of IFN- γ 
responses to PPDs  by control (n=5) as well as, M. bovis Ravenel (n=5), M. bovis 95-
1315infected (n=5) animals pooled over time. b) Comparison of IFN- γ responses to 
PPDs by control (n=7) as well as, M. bovis 95-1315 (n=8), and M. bovis 10-7428 infected 
(n=8), animals pooled over time. PPDa refers to M. avium derived PPD, PPDb refers to 
M. bovis derived PPD, and B-A indicates values for PPDb-PPDa 
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Table 1: Number of positive animals per group after challenge using CSL and Lelystad 
PPDs when samples were not diluted and diluted. 
 
Animals were considered positive when PPDa responses are subtracted from PPDb 
responses and the difference in OD450 was greater than 0.1. 
*Some animals within the experimentally infected groups were still at the maximum limit 
of detection making it difficult to detect differences between PPDb and PPDa. 
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Figure 4: Comparison of PPDs using plasma dilutions at select time points after challenge 
and pooled over time to detect differences. a) Control (n=7). b) M. bovis 95-1315 
challenged animals (n=8). c) M. bovis 10-7428 challenged animals. Data are presented as 
responses to PPDb minus PPDa (B-A). 
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Figure 5: Evaluation of IFN-γ responses in samples obtained from dairy cattle within 
tuberculosis-affected herds (i.e. natural infection). Comparison of CSL (Commonwealth 
Serum Laboratories) and Lelystad (Prionics AG) M. avium derived PPD (PPDa) and M. 
bovis derived PPD (PPDb). a) Data were pooled from two outbreaks in California (n=710 
and n=73), and one in Washington (n=11). All animals were considered tuberculosis-
exposed, as tuberculosis-infected animals had been removed from these herds. Samples 
from animals with no stimulation responses exceeding responses to PPDa and PPDb were 
excluded (n=10). b) Data were pooled from infected and exposed animals from Colorado. 
Animals were categorized based on positive culture of M. bovis (Infected, n=56) or 
having been in contact with known infected animals (Exposed, n=70). 
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Figure 6: Comparison of current (B1G) and new (B2G) Bovigam (Prionics AG) kits 
using responses to individual antigens and PPDb-PPDa with samples from control (n=7) 
as well as, M. bovis 95-1315 (n=8), and M. bovis 10-7428 infected (n=8) animals. a) IFN- 
γ responses pooled over time. b) Pre-challenge CSL and Lelystad PPDb-PPDa responses 
c) 4 week post-challenge CSL and Lelystad PPDb-PPDa responses d) 12 weeks post-
challenge CSL and Lelystad PPDb-PPDa responses. 
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Supplemental 1: Comparison of IFN-γ responses to PC-HP and PC-EC in control (n=7) 
as well as, M. bovis 95-1315 (n=8), and M. bovis 10-7428 infected (n=8) animals. a) 
Responses over time b) Pooled over time. 
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Supplemental 2: IFN-γ responses to CSL and Lelystad (LEL) PPDs. a) Responses at 3, 4, 
and 6 weeks post-challenge in control (n=5) as well as, M. bovis Ravenel (n=5), and M. 
bovis 95-1315 infected (n=5) animals. b) Responses at 3, 6 and 12 weeks post-challenge 
in control (n=7) as well as, M. bovis 95-1315 (n=8),  and M. bovis 10-7428 infected (n=8) 
animals. 
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CHAPTER 3: GENERAL CONCLUSIONS 
General Discussion 
This thesis was aimed at evaluating Mtbc-specific antigens as well as PPDs from 
different manufacturers’ to improve the diagnostic ability of the IFN-γ assay to detect 
bovine TB. In this study it was determined that the two peptide cocktails tested 
containing Mtbc-specific antigens and the two PPDs tested were equally effective in 
detecting bovine TB in experimentally infected cattle using M. bovis strains that differed 
in virulence. Peptide cocktails were shown to detect infection as early as three weeks 
after M. bovis challenge. It was also of note that adding Rv3615c and three other 
mycobacterium-specific antigens into a peptide cocktail with ESAT-6 and CFP-10 
resulted in comparable diagnostic capability as a peptide cocktail composed of only 
ESAT-6 and CFP-10.  
PPDs were further compared using samples from cattle herds that had been in 
contact with an M. bovis infected animal that was detected by slaughterhouse 
surveillance. It was determined that although both were successful in detecting bovine 
TB, Lelystad PPDs classified more animals as positive then CSL PPDs respectively. This 
finding brings back the point that not all PPDs perform the same that has been 
demonstrated by previously (2, 3, 6).  
These experimental studies also demonstrated that reactions to conserved 
mycobacterial antigens can result in misinterpretation of the IFN-γ assay when using 
PPDs alone. The high responses to avian PPD due to conserved antigens resulted in the 
failure to detect experimentally-challenged cattle once PPDb-PPDa calculations were 
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performed. However, this study demonstrates that dilution of the stimulated plasma is an 
effective means to detect M. bovis infected cattle when there are robust responses to 
conserved antigens. This is an important discovery as the presence of high numbers of 
environmental mycobacteria in some geographical regions greatly hinders the 
performance of the IFN-γ assay as a diagnostic tool. 
Recommendations for Future Research 
 This thesis examined ways to improve the diagnostic capability of the IFN-γ assay 
using a controlled experimental-challenge model. However, further studies are needed 
using naturally infected animals, BCG vaccinated animals, and cattle under the age of six 
months as these are the areas in which improved diagnostics are needed.  
 The goal of the TB eradication and control programs are generally focused on 
improved ante-mortem testing. IFN-γ responses elicited to peptide cocktails in 
experimental-challenge studies may be much higher than those responses elicited by 
naturally infected cattle that could decrease their ability to detect infection. In this study, 
lesions were seen at 13 weeks post-challenge signifying the development of an immune 
response over time that can be measured. In natural infection, it is not known how long 
an animal has been infected, infectious dose, or the time it took for visible lesions to 
form. Therefore, animals being tested in the field may not elicit as robust as a response as 
seen in experimental studies.  
 This study tested DIVA reagents in an experimental challenge setting without 
BCG vaccination. It would be interesting to examine the same reagents in BCG 
vaccinated animals that are later challenged with M. bovis to determine if they are still 
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capable of detecting infection. These studies would help examine the potential of 
vaccinating all cattle as a means of prevention without affecting the performance of 
diagnostic assays (5). It would also be interesting to test DIVA reagents in infected 
animals less than six months in age. Current testing of this age group using the IFN-γ 
assay and PPD results in non-specific responses; however, this response wanes with age 
(1, 4). This makes it difficult to test herds with young animals that had contact with an 
infected animal using the IFN-γ assay. Responses to DIVA reagents by young animals 
have not been done and would further test if these reagents are capable of detecting 
infection at a young age. 
 Experimentally challenged animals elicit robust IFN-γ responses to both PPDa 
and PPDb due to conserved mycobacterium antigens. This study found that by diluting 
stimulated plasma resulted in improved ability to detect infection by bringing the 
responses down to a measurable level. This procedure could be incorporated into regions 
where there are high levels of non-pathogenic mycobacteria that obstruct detection of 
bovine TB using the IFN-γ assay. However, further studies are needed using animals 
from those regions. 
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